Rayno Life Science Stocks Move Higher: CLVS, RHHBY- ASCO Preview
May 14, 2015 at 20:30 PM EDT
CLVS - with a valuation of only $3.4B and three platform products in the pipeline including companion diagnostics the Company is on “hit lists” to be acquired. CLVS was added to the Rayno Portfolio on January 13, 2015 at a price of $60.